Percorrer por autor "Silva, Ana Margarida"
A mostrar 1 - 2 de 2
Resultados por página
Opções de ordenação
- Pickering emulsions stabilized with chitosan/collagen peptides nanoparticles as green topical delivery vehicles for cannabidiol (CBD)Publication . Sharkawy, Asma; Silva, Ana Margarida; Rodrigues, Francisca; Barreiro, M.F.; Rodrigues, AlírioPickering emulsions (PEs) are attracting increasing attention in the areas of food, cosmetic and pharmaceutical applications owing to their surfactant-free and eco-friendly nature. Herein, PEs stabilized by chitosan/collagen peptides (CH/CP) nanoparticles were assessed as green surfactant-free vehicles for the topical delivery of cannabidiol (CBD), a highly lipophilic unstable drug that is finding an increasing appeal in the cosmetic market. The influence of the oil phase volume fraction (φ) and the oil type on the emulsion properties, stability, rheological properties, as well as on the ex-vivo skin absorption of CBD was evaluated. The PE prepared with olive oil (φ = 0.6) exhibited elastic gel-like properties and demonstrated long-term stability after 5 months of storage, with a CBD content of 99.45% of the initially added amount. The skin absorption studies showed that CBD was retained in high amounts in the stratum corneum, while the CBD skin permeation was extremely low, indicating that the produced formulations are suitable as topical delivery vehicles. ATR-FTIR examination of the treated skin samples confirmed that the produced PEs were able to overcome the stratum corneum barrier. These findings suggest that the PEs stabilized with CH/CP nanoparticles provide an effective surfactant-free alternative for the topical delivery of CBD.
- Tracing the path between mushrooms and Alzheimer's disease-a literature reviewPublication . Silva, Ana Margarida; Preto, Marco; Grosso, Clara; Vieira, Monica; Delerue-Matos, Cristina; Vasconcelos, Vítor; Reis, Mariana; Barros, Lillian; Martins, RosarioAlzheimer's disease (AD) is well-known among neurodegenerative diseases for the decline of cognitive functions, making overall daily tasks difficult or impossible. The disease prevails as the most common form of dementia and remains without a well-defined etiology. Being considered a disease of multifactorial origin, current targeted treatments have only managed to reduce or control symptoms, and to date, only two drugs are close to being able to halt its progression. For decades, natural compounds produced by living organisms have been at the forefront of research for new therapies. Mushrooms, which are well-known for their nutritional and medicinal properties, have also been studied for their potential use in the treatment of AD. Natural products derived from mushrooms have shown to be beneficial in several AD-related mechanisms, including the inhibition of acetylcholinesterase (AChE) and & beta;-secretase (BACE 1); the prevention of amyloid beta (A & beta;) aggregation and neurotoxicity; and the prevention of Tau expression and aggregation, as well as antioxidant and anti-inflammatory potential. Several studies in the literature relate mushrooms to neurodegenerative diseases. However, to the best of our knowledge, there is no publication that summarizes only AD data. In this context, this review aims to link the therapeutic potential of mushrooms to AD by compiling the anti-AD potential of different mushroom extracts or isolated compounds, targeting known AD-related mechanisms.